The European Ombudsman has rejected a complaint of maladministration by the European Commission. In 2009, the complainant asked the competition authorities in the Commission to investigate the disparity between the price of drugs, medicines and prescriptions in Ireland and those in other Member States. The Commission responded by explaining that there are various factors, including objective commercial factors, which can cause price differences and that the complainant had not demonstrated that the price discrepancy resulted from unjustified obstacles to trade. The complainant insisted that the Commission intervene because the Irish competition authorities had said that they were not competent to deal with cases between Ireland and other EU Member States. The Commission responded by saying that the Irish competition authority can, in principle, carry out investigations into alleged excessive pricing by a company, but they have the discretion not to do so since they are not price regulators and have limited resources. The Commission reiterated that there was insufficient information to launch an investigation. The complainant wrote to the Ombudsman requesting his intervention. On 12 August 2011, the Ombudsman concluded his investigation. He found that the Commission had responded in a timely manner to the complainant and provided adequate responses. Therefore, there had been no maladministration. Nevertheless, he suggested that it would have been more “citizen-friendly” if the Commission’s competition staff had suggested that the complainant contact their colleagues in DG Sanco, which administers and enforces EU health laws.